Journal Club: Rising Concerns about Cannabidiol and Liver Enzymes

Written By Jahan Marcu, PhD

Time: Tuesday, February 3rd, 2026 Noon EST     

Location – Virtual Meeting
https://us02web.zoom.us/j/83722922366?pwd=QjZ3V0xNWHZ0OVZ0b3BpbWd3STRqUT09

Event Description:

We will discuss a randomized double-blinded placebo-controlled trial to examine the effect of CBD on liver enzymes at doses at or near the upper end of over-the-counter CBD products. The study randomly assigned 201 healthy participants aged 18 to 55 years to CBD, 5 mg/kg/d (n = 151), or placebo (n = 50) for 28days.

Bring your questions and insights for an engaging discussion!

Featured Article:

Florian, J. et al. Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults. JAMA Intern. Med. 185, 1070–1078 (2025). https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2836267

Speakers:

  • Phil Molloy, MD – Clinical education expert

  • Teresa Simon, MPH – Public health epidemiologist

  • Len Kamen, MD – Clinical pain specialist

  • Jahan Marcu, PhD – Cannabis researcher

Questions? Email Prctrials.info@gmail.com

This journal club event is supported by PRC+. PRC + has education modules and other resources available for health care professionals: https://www.prc-trials-plus.com/education

Jahan Marcu, PhD
Previous

Cannabis and Alcohol Use: What a Randomized Trial Tells Us — and What It Doesn’t
Next

Older Adults, Cannabis, and the Quiet Gap in Clinical Conversations